delfidiagnostics.comHealthcare / Digital HealthFounded: 2019Funding to Date: $326.47MM
Delfi Diagnostics is a biotechnology company with a mission to use its technology for early cancer detection. By developing AI and ML algorithms, Delfi Diagnostics offers predictive testing processes with the goal of maximizing patient survival rates. The company specializes in the detection of breast cancer and aims to help healthcare organizations minimize treatment toxicity with less-invasive treatments. Delfi Diagnostics was founded by Alessandro Leal and Victor Velculescu in 2019 and is headquartered in Baltimore, MD.
View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Delfi Diagnostics.
Become part of the Secondary Marketplace, catering to both individual and institutional investors.